Developer docs
API playgroundTry for free, no card

Search company profiles

Newcells Biotech

Full company profile

uuid00028om

Namestring
Newcells Biotech
Legal namestring
Newcells Biotech Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Newcells Biotech, founded in 2015 and headquartered in Newcastle upon Tyne, United Kingdom, developed induced pluripotent stem cell (iPSC)-derived 3D human tissue models sold to pharmaceutical companies, biotechnology firms, and contract research organizations for preclinical drug safety and efficacy testing. The company's core technology centered on differentiating iPSCs into organ-specific 3D models covering the retina, kidney, lung, and liver, offering a physiologically relevant in vitro alternative to animal testing that aimed to reduce translational failure in drug development pipelines.

The product portfolio comprised 3D human tissue models and specialist research services delivered through direct enterprise sales to global pharmaceutical and biotech customers. Revenue was generated through one-time sales of tissue model products and professional research services for biopharma and biotech clients, with pricing handled via undisclosed B2B quote-based arrangements. The company's go-to-market motion relied on direct industry engagement, conference participation, and targeted US market expansion backed by repeated venture rounds from Mercia Asset Management, NorthStar Ventures, NVM Private Equity, and the North East Fund.

In February 2026, the company entered administration; Axol Bioscience acquired the ophthalmology (retinal) business out of administration, preserving the specialist team and related intellectual property, while 18 jobs were lost as the remaining non-retina operations ceased. As of the most recent reporting, Newcells Biotech no longer operates as an independent going concern.

Short descriptiontext

Newcells Biotech, founded in 2015 in Newcastle, UK, developed iPSC-derived 3D human tissue models (retina, kidney, lung, liver) for pharmaceutical, biotechnology, and CRO customers performing preclinical drug safety and efficacy testing as an alternative to animal models.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D tissue models, iPSC-derived cells, preclinical drug testing, animal testing alternatives, ophthalmology research models
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Testing Models
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
13D Human Tissue Model Sales
TypeOne Time License
Description

Sale of 3D human tissue models to pharmaceutical companies for drug safety and efficacy testing

business-live.co.uk
2Research Services
TypeProfessional Services
Description

Specialist research services for biopharma and biotech customers

newcastlehelix.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Newcells Biotech develops and supplies 3D human tissue models derived from induced pluripotent stem cells (iPSCs) for use in drug discovery and preclinical safety/efficacy testing. Its organ-specific product line covers retina, kidney, lung, and liver models that pharmaceutical, biotechnology, and CRO clients use as human-relevant alternatives to animal testing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Newcells Biotech is a biotech company founded in 2015 that develops 3D human tissue models as alternatives to animal testing for pharmaceutical drug development. The company produces a portfolio of tissue models including retina, kidney, lung, and liver tissues, which are used by pharmaceutical companies worldwide to test drug safety and efficacy. In February 2026, the ophthalmology (retina) business was acquired by Axol Bioscience.

Product and service5 records
1Retina 3D Tissue Models
CategoryOphthalmology research models
Description

iPSC-derived 3D retinal tissue models for ophthalmology research and preclinical drug testing, used by pharmaceutical and biotech customers and sold to Axol Bioscience as part of the February 2026 ophthalmology transaction.

2Kidney 3D Tissue Models
CategoryPreclinical drug testing models
Description

iPSC-derived 3D kidney tissue models for nephrotoxicity testing and renal drug safety assessment for pharmaceutical and biotech customers.

3Lung 3D Tissue Models
CategoryPreclinical drug testing models
Description

iPSC-derived 3D lung tissue models for respiratory research and drug discovery applications.

4Liver 3D Tissue Models
CategoryPreclinical drug testing models
Description

iPSC-derived 3D liver tissue models for hepatotoxicity testing and drug metabolism studies for pharmaceutical and biotech customers.

5iPSC-Derived Cell Models
CategoryStem cell biology platforms
Description

Induced pluripotent stem cell-derived cell models used by pharmaceutical, biotechnology, and academic customers as the cellular foundation for organ-specific 3D tissue model products and drug discovery research.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-12
Description

Axol Bioscience acquired the ophthalmology business from Newcells Biotech out of administration on February 12, 2026. The acquisition included specialist team, facilities, and intellectual property related to iPSC-derived retinal products and research services for biopharma and biotech customers. This marked Axol's third acquisition in five years.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch organ-on-chip company producing microfluidic 3D tissue models for toxicology and disease modeling. Directly comparable technology category and customer overlap with Newcells' kidney and liver model offerings.

2CN Bio Innovations
TypeDirect peer
Description

UK-based organ-on-chip company offering multi-organ microphysiological systems (liver, lung, gut) for drug safety and efficacy testing. Comparable as a UK-headquartered alternative-to-animal-testing platform targeting the same pharma preclinical customers.

TypeDirect peer
Description

Swiss 3D in vitro model company producing organotypic liver, pancreatic, and tumor microtissues used in pharma preclinical safety and efficacy testing. Directly comparable as an alternative-to-animal-testing 3D tissue platform.

TypeDirect peer
Description

UK-based developer of iPSC-derived hepatocyte and disease models for drug discovery, particularly liver and metabolic disease. Overlaps directly with Newcells' liver tissue model line and iPSC-derived cell business.

TypeDirect peer
Description

US-based organ-on-chip platform company commercialising the Emulate Chip for liver, kidney, lung, and intestinal models in pharma R&D. Comparable as a competing physiologically-relevant human tissue platform for preclinical testing.

TypeDirect peer
Description

Belgian/Dutch iPSC-derived cell provider (formed from Pluriomics and Axiogenesis) focused on cardiomyocytes, neurons, and other iPSC-derived cell models for drug discovery and safety testing. Closely comparable business model and customer base to Newcells.

TypeDirect peer
Description

Cambridge-based iPSC technology provider that acquired Newcells' ophthalmology business out of administration in February 2026. Directly comparable as a manufacturer of iPSC-derived cells and disease model services for pharma, biotech, and CROs, and now operates the rescued retinal organoid assets.

TypeOthers
Description

Global CDMO and cell & gene services provider offering iPSC-related manufacturing, cell banking, and assay services. A broad incumbent in the cell-based services and manufacturing space overlapping Newcells' offering.

TypeBroad incumbent
Description

Major pharma with substantial in-house organoid and iPSC programs and partnerships across ophthalmology and other therapeutic areas. Functions as a broad incumbent customer and occasional competitor in the iPSC-based drug discovery space.

TypeBroad incumbent
Description

Large global CRO offering preclinical safety and efficacy services including early-stage in vitro and cell-based assays for pharma. Competes with Newcells as a broad incumbent with deeper resources and broader service portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Newcells Biotech

Preclinical Drug Testing Modelsnewcellsbiotech.co.uk

Newcells Biotech, founded in 2015 in Newcastle, UK, developed iPSC-derived 3D human tissue models (retina, kidney, lung, liver) for pharmaceutical, biotechnology, and CRO customers performing preclinical drug safety and efficacy testing as an alternative to animal models.

What Newcells Biotech does

Newcells Biotech, founded in 2015 and headquartered in Newcastle upon Tyne, United Kingdom, developed induced pluripotent stem cell (iPSC)-derived 3D human tissue models sold to pharmaceutical companies, biotechnology firms, and contract research organizations for preclinical drug safety and efficacy testing. The company's core technology centered on differentiating iPSCs into organ-specific 3D models covering the retina, kidney, lung, and liver, offering a physiologically relevant in vitro alternative to animal testing that aimed to reduce translational failure in drug development pipelines.

The product portfolio comprised 3D human tissue models and specialist research services delivered through direct enterprise sales to global pharmaceutical and biotech customers. Revenue was generated through one-time sales of tissue model products and professional research services for biopharma and biotech clients, with pricing handled via undisclosed B2B quote-based arrangements. The company's go-to-market motion relied on direct industry engagement, conference participation, and targeted US market expansion backed by repeated venture rounds from Mercia Asset Management, NorthStar Ventures, NVM Private Equity, and the North East Fund.

In February 2026, the company entered administration; Axol Bioscience acquired the ophthalmology (retinal) business out of administration, preserving the specialist team and related intellectual property, while 18 jobs were lost as the remaining non-retina operations ceased. As of the most recent reporting, Newcells Biotech no longer operates as an independent going concern.

Newcells Biotech firmographics

Firmographics
Name
Newcells Biotech
Legal name
Newcells Biotech Limited
Website
https://newcellsbiotech.co.uk
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
Newcells Biotech, founded in 2015 in Newcastle, UK, developed iPSC-derived 3D human tissue models (retina, kidney, lung, liver) for pharmaceutical, biotechnology, and CRO customers performing preclinical drug safety and efficacy testing as an alternative to animal models.
Ownership category
akta.pro rank

Newcells Biotech industry classification

Industry
Product category
Preclinical Drug Testing Models
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • 3D tissue models
  • IPSC-derived cells
  • Preclinical drug testing
  • Animal testing alternatives
  • Ophthalmology research models

Where Newcells Biotech is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Newcells Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. 3D Human Tissue Model Sales: Sale of 3D human tissue models to pharmaceutical companies for drug safety and efficacy testing
  2. Research Services: Specialist research services for biopharma and biotech customers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Newcells Biotech product offering

Product offering

Core offering

Newcells Biotech develops and supplies 3D human tissue models derived from induced pluripotent stem cells (iPSCs) for use in drug discovery and preclinical safety/efficacy testing. Its organ-specific product line covers retina, kidney, lung, and liver models that pharmaceutical, biotechnology, and CRO clients use as human-relevant alternatives to animal testing.

Product overview

Newcells Biotech is a biotech company founded in 2015 that develops 3D human tissue models as alternatives to animal testing for pharmaceutical drug development. The company produces a portfolio of tissue models including retina, kidney, lung, and liver tissues, which are used by pharmaceutical companies worldwide to test drug safety and efficacy. In February 2026, the ophthalmology (retina) business was acquired by Axol Bioscience.

Differentiator

Problem solved

Functional benefit

Products and services

  • Retina 3D Tissue Models iPSC-derived 3D retinal tissue models for ophthalmology research and preclinical drug testing, used by pharmaceutical and biotech customers and sold to Axol Bioscience as part of the February 2026 ophthalmology transaction.
  • Kidney 3D Tissue Models iPSC-derived 3D kidney tissue models for nephrotoxicity testing and renal drug safety assessment for pharmaceutical and biotech customers.
  • Lung 3D Tissue Models iPSC-derived 3D lung tissue models for respiratory research and drug discovery applications.
  • Liver 3D Tissue Models iPSC-derived 3D liver tissue models for hepatotoxicity testing and drug metabolism studies for pharmaceutical and biotech customers.
  • iPSC-Derived Cell Models Induced pluripotent stem cell-derived cell models used by pharmaceutical, biotechnology, and academic customers as the cellular foundation for organ-specific 3D tissue model products and drug discovery research.

Companies that use Newcells Biotech

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Newcells Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Newcells Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Axol BiosciencecoreStrategic or Co-development Partner · 12 February 2026Axol Bioscience acquired the ophthalmology business from Newcells Biotech out of administration on February 12, 2026. The acquisition included specialist team, facilities, and intellectual property related to iPSC-derived retinal products and research services for biopharma and biotech customers. This marked Axol's third acquisition in five years.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Newcells Biotech competitors and assessment

Company assessment

Direct peers

  • Mimetas: Dutch organ-on-chip company producing microfluidic 3D tissue models for toxicology and disease modeling. Directly comparable technology category and customer overlap with Newcells' kidney and liver model offerings.
  • CN Bio Innovations: UK-based organ-on-chip company offering multi-organ microphysiological systems (liver, lung, gut) for drug safety and efficacy testing. Comparable as a UK-headquartered alternative-to-animal-testing platform targeting the same pharma preclinical customers.
  • InSphero: Swiss 3D in vitro model company producing organotypic liver, pancreatic, and tumor microtissues used in pharma preclinical safety and efficacy testing. Directly comparable as an alternative-to-animal-testing 3D tissue platform.
  • DefiniGEN: UK-based developer of iPSC-derived hepatocyte and disease models for drug discovery, particularly liver and metabolic disease. Overlaps directly with Newcells' liver tissue model line and iPSC-derived cell business.
  • Emulate Inc. US-based organ-on-chip platform company commercialising the Emulate Chip for liver, kidney, lung, and intestinal models in pharma R&D. Comparable as a competing physiologically-relevant human tissue platform for preclinical testing.
  • Ncardia: Belgian/Dutch iPSC-derived cell provider (formed from Pluriomics and Axiogenesis) focused on cardiomyocytes, neurons, and other iPSC-derived cell models for drug discovery and safety testing. Closely comparable business model and customer base to Newcells.
  • Axol Bioscience: Cambridge-based iPSC technology provider that acquired Newcells' ophthalmology business out of administration in February 2026. Directly comparable as a manufacturer of iPSC-derived cells and disease model services for pharma, biotech, and CROs, and now operates the rescued retinal organoid assets.

Others

  • Lonza Group: Global CDMO and cell & gene services provider offering iPSC-related manufacturing, cell banking, and assay services. A broad incumbent in the cell-based services and manufacturing space overlapping Newcells' offering.

Broad incumbents

  • F. Hoffmann-La Roche: Major pharma with substantial in-house organoid and iPSC programs and partnerships across ophthalmology and other therapeutic areas. Functions as a broad incumbent customer and occasional competitor in the iPSC-based drug discovery space.
  • Charles River Laboratories: Large global CRO offering preclinical safety and efficacy services including early-stage in vitro and cell-based assays for pharma. Competes with Newcells as a broad incumbent with deeper resources and broader service portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

Newcells Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Newcells Biotech leadership team

Management profile

Number of profiles

Profiles3 records

Newcells Biotech funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Newcells Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newcells Biotech

What does Newcells Biotech do?

Newcells Biotech develops and supplies 3D human tissue models derived from induced pluripotent stem cells (iPSCs) for use in drug discovery and preclinical safety/efficacy testing. Its organ-specific product line covers retina, kidney, lung, and liver models that pharmaceutical, biotechnology, and CRO clients use as human-relevant alternatives to animal testing.

Is Newcells Biotech a public or private company?

Newcells Biotech is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Newcells Biotech founded?

Newcells Biotech was founded in 2015. It employs 11 to 50 people.

Where is Newcells Biotech based?

Newcells Biotech is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does Newcells Biotech make money?

Two revenue lines are on record. 3D Human Tissue Model Sales are the primary driver. The others are research Services.

Who are Newcells Biotech's main competitors?

Direct peers on record are Mimetas, CN Bio Innovations, InSphero, DefiniGEN, Emulate Inc., Ncardia and Axol Bioscience. Lonza Group is listed as an others. Broad incumbents are F. Hoffmann-La Roche and Charles River Laboratories.

Does Newcells Biotech have an API?

No public API is recorded for Newcells Biotech.

What industry is Newcells Biotech in?

Newcells Biotech's product category is Preclinical Drug Testing Models. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Axol Bioscience Acquires Newcells Biotech’s Ophthalmology BusinessAxol Bioscience acquired Newcells Biotech's ophthalmology business, expanding its iPSC-derived retinal organoid and retinal pigment epithelium models. The deal adds Newcells' team, facilities, and IP for ophthalmology research services, supporting biopharma and CRO customers. It strengthens Axol's position in ophthalmology drug discovery and safety testing.InsidermediaAxol Bioscience acquires ophthalmology business from Newcells BiotechAxol Bioscience, a Cambridge-based biotech specializing in human iPSC technologies, has acquired the ophthalmology business from Newcells Biotech, a drug discovery partner in Newcastle. The acquisition includes the specialist team, facilities, and intellectual property related to iPSC-derived retinal products and research services for biopharma and biotech customers. This marks Axol's third acquisition in five years and follows a recent £2.1m funding round led by BroadOak Capital Partners.Business LiveJobs saved at Newcastle life sciences firm Newcells Biotech amid partial rescue dealJobs were saved at Newcastle life sciences firm Newcells Biotech after Cambridge-based Axol Bioscience Ltd acquired its ophthalmology business out of administration on February 12, 2026. The partial rescue deal saved the retina division and its specialist team, but 18 other jobs were lost as the remaining operations of the company ceased. The acquisition expands Axol's portfolio in physiologically-relevant in vitro retinal models for ophthalmology drug discovery and safety testing.PharmaTimesAxol Bioscience acquires Newcells Biotech ophthalmology unitAxol Bioscience has acquired the ophthalmology business of Newcells Biotech, a deal announced in the UK on 18 February 2026 that expands its portfolio of induced pluripotent stem cell-derived retinal models for preclinical eye disease research. The acquisition brings Axol a specialist team, facilities, and intellectual property including advanced retinal organoids and 2D retinal pigment epithelium models serving biopharma, biotechnology, and CRO customers in Europe and the United States. The deal represents Axol's third acquisition in five years and follows a recent $2.8 million financing led by BroadOak Capital Partners, supporting the company's strategy to scale internationally and deepen its scientific capabilities in ophthalmology drug discovery.News-MedicalNewcells Biotech raises additional funding from investorsNewcells Biotech raised £1.2m from existing investors Mercia Ventures, Northstar Ventures, and North East Finance. The funds will support expansion and new partnerships, with Dr. Mark Carnegie-Brown appointed chairman. The company expects continued demand for non-animal drug testing methods.BusinessCloudNewcells bags another £1.2m for lab models that replace animal testingNewcells Biotech raised £1.2m from existing investors Mercia Ventures, Northstar Ventures, and North East Finance. The Newcastle-based company's 3D lab models replace animal testing in drug development, bringing total funding to over £13m. The company plans to expand its customer base and seek partnerships.BusinessCloudNewcells bags another £1.2m for lab models that replace animal testingNewcells Biotech raised £1.2m from existing investors to expand its customer base and partnerships. The Newcastle-based company, which offers 3D lab models to replace animal testing, has now raised over £13m since 2015. The funding aims to exploit growing demand as more companies move away from animal testing.BusinessCloudNewcells bags another £1.2m for lab models that replace animal testingNewcells Biotech raised £1.2m from existing investors to expand its 3D lab models that replace animal testing in drug development. The funding brings total raised to over £13m and will support customer growth and partnerships. The company expects demand to continue as more firms adapt away from animal testing.Business LiveNewcells Biotech secures £1.2m follow-on investment to build customer baseNewcells Biotech raised £1.2m from existing investors Mercia Ventures, Northstar Ventures, and North East Finance. The funds will build its customer base and develop partnerships, with Mark Carnegie-Brown appointed chair. The company's 3D tissue models aim to reduce reliance on animal testing.Cambridge NetworkNewcells Biotech raises additional funding from investorsNewcells Biotech has raised an additional £1.2m in funding from existing investors Mercia Ventures, Northstar Ventures, and North East Finance to support expansion and technological innovation. The capital will be used to build its customer base and seek partnerships for international markets, coinciding with the appointment of Dr. Mark Carnegie-Brown as Chairman. This growth is driven by increased market demand for non-animal testing methods following regulatory changes such as the US FDA's Modernization Act 2.0.